Globus Medical, Inc. (GMED)
NYSE: GMED · Real-Time Price · USD
90.74
-2.96 (-3.16%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Globus Medical Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for Globus Medical stock have an average target of 100.42, with a low estimate of 64 and a high estimate of 123. The average target predicts an increase of 10.67% from the current stock price of 90.74.
Analyst Consensus: Buy
* Price targets were last updated on Feb 26, 2026.
Analyst Ratings
The average analyst rating for Globus Medical stock from 14 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 6 | 5 | 5 | 5 |
| Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Hold | 4 | 5 | 4 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 16 | 15 | 14 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Maintains $98 → $104 | Buy | Maintains | $98 → $104 | +14.61% | Feb 26, 2026 |
| Barclays | Barclays | Buy Maintains $118 → $123 | Buy | Maintains | $118 → $123 | +35.55% | Feb 25, 2026 |
| Needham | Needham | Strong Buy Maintains $112 → $114 | Strong Buy | Maintains | $112 → $114 | +25.63% | Feb 25, 2026 |
| Needham | Needham | Hold → Strong Buy Upgrades $112 | Hold → Strong Buy | Upgrades | $112 | +23.43% | Jan 30, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $105 → $112 | Strong Buy | Maintains | $105 → $112 | +23.43% | Jan 9, 2026 |
Financial Forecast
Revenue This Year
3.27B
from 2.94B
Increased by 11.13%
Revenue Next Year
3.47B
from 3.27B
Increased by 6.28%
EPS This Year
4.56
from 3.92
Increased by 16.32%
EPS Next Year
5.06
from 4.56
Increased by 10.86%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 3.4B | 3.7B | |||
| Avg | 3.3B | 3.5B | |||
| Low | 3.1B | 3.3B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 15.0% | 11.9% | |||
| Avg | 11.1% | 6.3% | |||
| Low | 6.5% | 0.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 4.79 | 5.37 | |||
| Avg | 4.56 | 5.06 | |||
| Low | 4.36 | 4.73 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 22.1% | 17.8% | |||
| Avg | 16.3% | 10.9% | |||
| Low | 11.2% | 3.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.